- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05273944
Bioequivalence Study of Doxorubicin Hydrochloride Liposome Injection (Lipodox®) in Chinese Patients
March 8, 2022 updated by: Shenzhen Kangzhe Pharmaceutical Co., Ltd.
A Randomized, Open-label, Single-dose, Two-preparation, Two-sequence, Two-cycle Crossover, Bioequivalence Study of Doxorubicin Hydrochloride Liposome Injection in Patients With Breast Cancer/Ovarian Cancer
Bioequivalence study is proposed to be carried out on patients of breast cancer/ ovarian cancer, who are administrated for Doxorubicin Hydrochloride Liposomal Injection Lipodox® or Caelyx® in a dose of 50 mg/m2.
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Detailed Description
This study is a randomized, open-label, single-dose, two-preparation, two-sequence, two-cycle crossover bioequivalence study.
This study will be conducted in female subjects aged 18 to 75 years diagnosed with breast cancer/ ovarian cancer.
Each subject will be randomized to two treatment sequences (RT or TR) with equal numbers of patients according to a randomization scheme prepared to start of the trial.
The cleaning period was 28-42 days.
Serial blood samples for determination of free and liposomal encapsulated doxorubicin plasma concentration for PK analysis will be obtained in each cycle.
Blood samples to be obtained at 0 h (within 60 min) before infusion, 15 min, 30 min, 45 min, 60 min, 75 min, 90min after the beginning of infusion, 15 min, 30 min, 1.0 h, 3.0 h, 5.0 h, 8.0 h, 16.0 h, 24.0 h, 36.0 h, 48.0 h, 96.0 h, 168.0 h, 240.0 h, 336.0 h after infusion completed.
Study Type
Interventional
Enrollment (Anticipated)
80
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Herui Yao
- Phone Number: 020 81332107
- Email: yaoherui@163.com
Study Locations
-
-
Guangdong
-
Guangzhou, Guangdong, China, 510120
- Recruiting
- Sun Yat-Sun Memorial Hospital, Sun Yat-Sun University
-
Contact:
- Herui Yao
- Phone Number: 020 81332107
- Email: yaoherui@163.com
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 75 years (ADULT, OLDER_ADULT)
Accepts Healthy Volunteers
No
Genders Eligible for Study
Female
Description
Inclusion Criteria:
- The subjects fully understand the purpose, nature, methods and possible adverse reactions of the study, voluntarily participate in the study, and sign informed consent before the study procedure begins;
- Adult female subjects between 18 to 75 years of age (both inclusive) at the time of screening visit. Body weight is greater than or equal to 40.0 kg. Body surface area (BSA) is less than 1.8 m2;
- Subjects with histologically or cytological proven: 1) Advanced ovarian cancer patients who had previously failed first-line platinum-containing chemotherapy; Or 2) metastatic breast cancer;
- ECOG performance status ≤ 2;
- Life expectancy of at least 3 months;
Adequate renal, hepatic function:
- Neutrophils ≥1.5×109/L;
- Leukocyte≥3×109/L;
- Platelet count ≥ 80×109/L;
- Hemoglobin (Hb) ≥ 90g/L;
- Serum creatinine ≤ 1.5 x ULN;
- AST ≤ 2.5 x ULN, ALT ≤ 2.5 x ULN (for liver metastasis≤ 5 x ULN);
- Prothrombin time (PT)/activated partial thromboplastin time (APTT) ≤ 1.5 x ULN;
- Total bilirubin≤ 1.5 x ULN (for liver metastasis≤ 3 x ULN);
- Alkaline phosphatase ≤ 2.5 x ULN;
- Subjects (including spouse) who have no childbearing plans in the next 6 months and voluntarily take effective contraceptive measures.
Exclusion Criteria:
- History of allergy to doxorubicin or any components of doxorubicin; or those with allergic constitution: such as those who are allergic to two or more drugs and food;
- Previous treatment with Doxorubicin Liposome, and discontinue treatment due to treatment failure or severe adverse reactions;
- Patients who have previously received more than 400 mg/m2 doxorubicin (Conversion of other anthracyclines and anthraquinone: 1 mg doxorubicin is equivalent to 2 mg epirubicin, or 2 mg pirarubicin, or 2 mg daunorubicin, or 0.5 mg dimethoxy-daunorubicin , or 0.45 mg mitoxantrone), or severe cardiotoxicity from prior exposure to anthracyclines;
- Positive history of known spinal cord compression or brain metastases (unless asymptomatic, stable for more than 4 weeks, steroid treatment was discontinued at least 4 weeks prior to first administration of Lipodox®/ Caelyx®, and no radiographic evidence of significant edema around the tumor lesion). Untreated patients with disease progression due to brain metastases in the last treatment prior to screening;
- Subjects with other known active malignancies that require treatment within 5 years;
- Patients with abnormal cardiac function: ECG examination, QTc>480ms; left ventricular ejection fraction(LVEF)<55%;congestive heart failure, myocardial infraction, or uncontrolled angina pectoris of New York Heart Society≥2 within 6 months prior to enrollment; have undergone heart bypass surgery; Tropoin≥1.5 x ULN;N-terminal brain natriuretic peptide ≥1.5 x ULN; The investigator evaluated the overall cardiac function of the subjects by integrating all examination items.
- Patients with poor control of hypertension (systolic≥160 mmHg, diastolic>80 mmHg;
- Diabetes blood glucose control is not up to standard, fasting blood glucose >11.1 mol/L, or accompanied by diabetic complications (diabetic nephropathy, peripheral neuropathy);
- Radiation therapy or chemotherapy drugs (paclitaxel, cyclosporine, dexrazoxane, cytarabine, streptozotocin, etc.) within 4 weeks before study administration prior to administration, or other anti-tumor therapies such as endocrine therapy, traditional Chinese medicine, and local radiation therapy to relieve pain;
- Patients who have undergone major surgery ≤ 4 weeks prior to starting study drug, or plan to undergo major surgery during the study period and those who have undergone surgery that may affect drug absorption, distribution, metabolism, and excretion;
- Use of drugs that induce or inhibit liver drug enzymes in the previous 4 weeks prior to administration and during the study (such as: Barbiturates, carbamazepine, phenytoin, griseofulvin);
- The special diet within 7 days before the study administration may affect drug absorption, distribution, metabolism and excretion during the study, including but no limited to: taking special diets that may image drug metabolism including dragon fruit, mango, grapefruit, lime, carambola, chocolate, or by the preparation of food or drink, or a diet containing caffeine, xanthine, etc;
- Patients who consumed excessive amounts of tea, coffee, and/or caffeine-rich beverages (more than 8 cups, one cup=250mL) daily for 3 months prior to administration;
- Patients who smoked more than 5 cigarettes per day during the 3 months prior to administration, or who did not agree to refrain from using any tobacco products during the study;
- Drinking more than 14 units of alcohol per week in the 3 months prior to administration (1 unit of alcohol≈360mL beer or 45mL 40% alcoholic spirits or 150mL wine);
- Pregnant women, breast-feeding women or women of childbearing age who are screened for positive pregnancy tests, or who do not agree to use effective contraceptive measures during the trial or whose spouse plans to give birth within 6 months;
- Patients with positive hepatitis B virus surface antigen (HBsAg) test results and HBV-DNA ≥104 copy number or ≥2000IU/ML, or those with other active infectious diseases (such as hepatitis C, syphilis, or human immunodeficiency virus HIV infection);
- Subjects who received vaccine within 1 month prior to administration;
- Previous history of drug abuse;
- Patients who cannot withstand venipuncture, have a history of needle sickness and blood sickness, or have difficulty in venous blood collection;
- Patients who had donated blood or lost blood of ≥400mL within 3 months prior to administration, or intended to donate blood (including blood components) during 3 months after the study;
- The investigator determined that subjects were unsuitable for this study.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: CROSSOVER
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Reference product-R
Caelyx® (Janssen-Cilag International NV); 20 mg/10 mL (50 mg/m2 dose).
As this is a crossover study, subjects receiving the Reference Product (Caelyx®) in Cycle 1, will receive the Test Product (Lipodox®) in Cycle 2. Cycle is defined as 28-42 days (RT).
|
50mg/m2, intravenous drip on Day 1 of each cycle.
On Day 1 of Cycle 1 patients will receive either reference or test product.
On Day 1 of Cycle 2, patients will crossover to the alternate reference or test formulation.
To measure pharmacokinetic paratemers of Caelyx® versus Lipodox®.
Other Names:
|
Experimental: Test Product-T
Lipodox® (Sun Pharmaceutical Industries Ltd.); 20 mg/10 mL (50 mg/m2 dose).
As this is a crossover study, subjects receiving the Test Product (Lipodox®) in Cycle 1, will receive the Reference Product (Caelyx®) in Cycle 2. Cycle is defined as 28-42 days (TR).
|
50mg/m2, intravenous drip on Day 1 of each cycle.
On Day 1 of Cycle 1 patients will receive either reference or test product.
On Day 1 of Cycle 2, patients will crossover to the alternate reference or test formulation.
To measure pharmacokinetic paratemers of Caelyx® versus Lipodox®.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Cmax
Time Frame: Pre-dose (within 60 minutes), 15,30, 45,60,75,90minutes after the beginning of infusion, 15minutes, 30minutes, 1,3,5,8,16,24,36,48,96,168,240,336hours after infusion completed
|
Maximum observed plasma concentration
|
Pre-dose (within 60 minutes), 15,30, 45,60,75,90minutes after the beginning of infusion, 15minutes, 30minutes, 1,3,5,8,16,24,36,48,96,168,240,336hours after infusion completed
|
AUC[0-t]
Time Frame: Pre-dose (within 60 minutes), 15,30, 45,60,75,90minutes after the beginning of infusion, 15minutes, 30minutes, 1,3,5,8,16,24,36,48,96,168,240,336hours after infusion completed
|
Area under the plasma concentration-time curve from time 0 to last time of quantifiable concentration
|
Pre-dose (within 60 minutes), 15,30, 45,60,75,90minutes after the beginning of infusion, 15minutes, 30minutes, 1,3,5,8,16,24,36,48,96,168,240,336hours after infusion completed
|
AUC[0-∞]
Time Frame: Pre-dose (within 60 minutes), 15,30, 45,60,75,90minutes after the beginning of infusion, 15minutes, 30minutes, 1,3,5,8,16,24,36,48,96,168,240,336hours after infusion completed
|
Area under the plasma concentration-time curve from 0 extrapolated to infinite time
|
Pre-dose (within 60 minutes), 15,30, 45,60,75,90minutes after the beginning of infusion, 15minutes, 30minutes, 1,3,5,8,16,24,36,48,96,168,240,336hours after infusion completed
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
AUC[0-48hours]
Time Frame: Pre-dose (within 60 minutes) , 15, 30, 45, 60, 75, 90minutes after the beginning of infusion, 15 minutes, 30 minutes, 1, 3, 5, 8, 16, 24, 36, 48hours after infusion completed
|
Area under the plasma concentration-time curve from time of intake until 48hours post-dose
|
Pre-dose (within 60 minutes) , 15, 30, 45, 60, 75, 90minutes after the beginning of infusion, 15 minutes, 30 minutes, 1, 3, 5, 8, 16, 24, 36, 48hours after infusion completed
|
AUC[48hours-t]
Time Frame: 48hours post-dose to the 336hours post-dose
|
Area under the plasma concentration-time curve from time of 48hours post-dose until the 336hours posy-dose
|
48hours post-dose to the 336hours post-dose
|
Tmax
Time Frame: Pre-dose (within 60 minutes), 15,30, 45,60,75,90minutes after the beginning of infusion, 15minutes, 30minutes, 1,3,5,8,16,24,36,48,96,168,240,336hours after infusion completed
|
Time to reach the maximum observed plasma concentration
|
Pre-dose (within 60 minutes), 15,30, 45,60,75,90minutes after the beginning of infusion, 15minutes, 30minutes, 1,3,5,8,16,24,36,48,96,168,240,336hours after infusion completed
|
λz
Time Frame: Pre-dose (within 60 minutes), 15,30, 45,60,75,90minutes after the beginning of infusion, 15minutes, 30minutes, 1,3,5,8,16,24,36,48,96,168,240,336hours after infusion completed
|
Elimination rate constant
|
Pre-dose (within 60 minutes), 15,30, 45,60,75,90minutes after the beginning of infusion, 15minutes, 30minutes, 1,3,5,8,16,24,36,48,96,168,240,336hours after infusion completed
|
t1/2z
Time Frame: Pre-dose (within 60 minutes), 15,30, 45,60,75,90minutes after the beginning of infusion, 15minutes, 30minutes, 1,3,5,8,16,24,36,48,96,168,240,336hours after infusion completed
|
Elimination half-life
|
Pre-dose (within 60 minutes), 15,30, 45,60,75,90minutes after the beginning of infusion, 15minutes, 30minutes, 1,3,5,8,16,24,36,48,96,168,240,336hours after infusion completed
|
AUC_%Extrap
Time Frame: Pre-dose (within 60 minutes), 15,30, 45,60,75,90minutes after the beginning of infusion, 15 minutes, 30 minutes, 1,3,5,8,16,24,36,48,96,168,240,336 hours after infusion completed
|
Percentage of remaining area,Calculate as [(AUC[0-∞]- AUC[0-t])/ AUC[0-∞]]×100%
|
Pre-dose (within 60 minutes), 15,30, 45,60,75,90minutes after the beginning of infusion, 15 minutes, 30 minutes, 1,3,5,8,16,24,36,48,96,168,240,336 hours after infusion completed
|
CL/F
Time Frame: Pre-dose (within 60 minutes), 15,30, 45,60,75,90 minutes after the beginning of infusion, 15 minutes, 30 minutes, 1,3,5,8,16,24,36,48,96,168,240,336 hours after infusion completed
|
Apparent clearance
|
Pre-dose (within 60 minutes), 15,30, 45,60,75,90 minutes after the beginning of infusion, 15 minutes, 30 minutes, 1,3,5,8,16,24,36,48,96,168,240,336 hours after infusion completed
|
Vd/F
Time Frame: Pre-dose (within 60 minutes), 15,30, 45,60,75,90 minutes after the beginning of infusion, 15 minutes, 30 minutes, 1,3,5,8,16,24,36,48,96,168,240,336 hours after infusion completed
|
Apparent volume of distribution
|
Pre-dose (within 60 minutes), 15,30, 45,60,75,90 minutes after the beginning of infusion, 15 minutes, 30 minutes, 1,3,5,8,16,24,36,48,96,168,240,336 hours after infusion completed
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Collaborators
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
July 28, 2021
Primary Completion (Anticipated)
March 31, 2022
Study Completion (Anticipated)
April 30, 2022
Study Registration Dates
First Submitted
February 10, 2022
First Submitted That Met QC Criteria
March 8, 2022
First Posted (Actual)
March 10, 2022
Study Record Updates
Last Update Posted (Actual)
March 10, 2022
Last Update Submitted That Met QC Criteria
March 8, 2022
Last Verified
February 1, 2022
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Skin Diseases
- Neoplasms by Histologic Type
- Neoplasms
- Urogenital Neoplasms
- Neoplasms by Site
- Carcinoma
- Neoplasms, Glandular and Epithelial
- Genital Neoplasms, Female
- Endocrine System Diseases
- Ovarian Diseases
- Adnexal Diseases
- Gonadal Disorders
- Endocrine Gland Neoplasms
- Breast Diseases
- Breast Neoplasms
- Ovarian Neoplasms
- Carcinoma, Ovarian Epithelial
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Antineoplastic Agents
- Topoisomerase II Inhibitors
- Topoisomerase Inhibitors
- Antibiotics, Antineoplastic
- Doxorubicin
- Liposomal doxorubicin
Other Study ID Numbers
- DHLI-BC/OC-BE-001
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Breast Cancer
-
Rutgers, The State University of New JerseyNational Cancer Institute (NCI); Rutgers Cancer Institute of New JerseyActive, not recruitingStage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IIA Breast Cancer | Stage IIB Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | HER2-negative Breast CancerUnited States
-
University of Southern CaliforniaNational Cancer Institute (NCI)TerminatedMale Breast Cancer | Stage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast CancerUnited States
-
Northwestern UniversityEisai Inc.UnknownMale Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | HER2-negative...United States
-
University of WashingtonTerminatedBreast Cancer | Breast Cancer Stage I | Breast Cancer Stage II | Breast Cancer Stage III | Breast Cancer Stage IIB | Breast Cancer Stage IIA | Breast Cancer Stage IIIA | Breast Cancer Stage IIIB | Breast Cancer Stage IIIcUnited States
-
CelgeneCompletedBreast Cancer | Metastatic Breast Cancer | Stage IV Breast Cancer | Triple-negative Breast Cancer | Recurrent Breast Cancer | Breast Tumor | Cancer of the Breast | Triple-negative Metastatic Breast Cancer | Estrogen Receptor- Negative Breast Cancer | HER2- Negative Breast Cancer | Progesterone Receptor- Negative...United States, United Kingdom, Italy, Germany, Spain, Canada, Portugal, Australia, Austria, Greece, Brazil, France
-
University of Southern CaliforniaNational Cancer Institute (NCI)TerminatedHER2-positive Breast Cancer | Stage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast CancerUnited States
-
University of WashingtonNational Cancer Institute (NCI)CompletedHER2-positive Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Estrogen Receptor-negative Breast Cancer | Estrogen Receptor-positive Breast Cancer | Progesterone Receptor-negative Breast Cancer | Progesterone Receptor-positive Breast...United States
-
University of WashingtonNational Cancer Institute (NCI)CompletedHER2-positive Breast Cancer | Male Breast Cancer | Stage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast CancerUnited States
-
Sidney Kimmel Cancer Center at Thomas Jefferson...Susan G. Komen Breast Cancer FoundationCompletedStage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | HER2-negative Breast CancerUnited States
-
Ohio State University Comprehensive Cancer CenterCompletedStage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IIA Breast Cancer | Stage IIB Breast Cancer | Stage IIIC Breast Cancer | Stage III Breast CancerUnited States
Clinical Trials on Doxorubicin Hydrochloride Liposome Injection
-
InxMed (Shanghai) Co., Ltd.Active, not recruitingLocally Advanced or Metastatic Solid TumorsChina
-
Ayana Pharma Ltd.,Lambda Therapeutic Research Ltd.CompletedOvarian Cancer RecurrentIndia
-
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.Completed
-
Fudan UniversityRecruitingAdvanced Malignant TumorsChina
-
Luye Pharma Group Ltd.CompletedAdvanced Breast CancerChina
-
Dr. Reddy's Laboratories LimitedCompletedOvarian Epithelial Cancer RecurrentIndia
-
TelikCompletedOvarian NeoplasmsUnited States, Czech Republic, South Africa, Argentina, Belgium, Spain, Brazil, Chile, Germany, Hungary, Ireland, Netherlands, United Kingdom
-
Tianjin Medical University Second HospitalCSPC Pharmaceutical Group LimitedUnknownMuscle Invasive Bladder CancerChina
-
Baxter Healthcare CorporationNot yet recruitingMultiple Myeloma | Ovarian Cancer | Metastatic Breast Cancer | AIDS-related Kaposi Sarcoma
-
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.Not yet recruitingFallopian Tube Cancer | Epithelial Ovarian Cancer | Peritoneal Cancer